Beam Therapeutics

BEAMNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.838 B

$27.48 +0.84%

Close of 7 Aug 2026

Revenue

$139.7M

#2418 by revenue

Earnings

-$80.0M

Loss-making

Shares outstanding

103,287,665

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#26Relay TherapeuticsRLAY$3.79B
#27Kodiak SciencesKOD$2.84B
#28Beam TherapeuticsBEAM$2.84B
#29Iovance BiotherapeuticsIOVA$2.83B
#30Tarsus PharmaceuticalsTARS$2.79B

Where these numbers come from

Share counts and financials for Beam Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.